A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

PRAX-114

40 mg once daily

DRUG

Placebo

Placebo once daily

Trial Locations (31)

3174

Praxis Research Site, Noble Park

10312

Praxis Research Site, Staten Island

11516

Praxis Research Site, Cedarhurst

14618

Praxis Research Site, Rochester

18104

Praxis Research Site, Allentown

19063

Praxis Research Site, Media

20877

Praxis Research Site, Gaithersburg

22903

Praxis Research Site, Charlottesville

30030

Praxis Research Site, Decatur

30331

Praxis Research Site, Atlanta

32256

Praxis Research Site, Jacksonville

32763

Praxis Research Site, Orange City

32801

Praxis Research Site, Orlando

38119

Praxis Research Site, Memphis

45417

Praxis Research Site, Dayton

60076

Praxis Research Site, Chicago

63368

Praxis Research Site, O'Fallon

78229

Praxis Research Site, San Antonio

78737

Praxis Research Site, Austin

85012

Praxis Research Site, Phoenix

89102

Praxis Research Site, Las Vegas

90660

Praxis Research Site, Pico Rivera

91945

Praxis Research Site, Lemon Grove

92056

Praxis Research Site, Oceanside

92374

Praxis Research Site, Redlands

92845

Praxis Research Site, Garden Grove

94549

Praxis Research Site, Lafayette

98201

Praxis Research Site, Everett

01655

Praxis Research Site, Worcester

08009

Praxis Research Site, Berlin

08053

Praxis Research Site, Marlton

Sponsors
All Listed Sponsors
lead

Praxis Precision Medicines

INDUSTRY